IL Receptor

(R)-IL-17 modulator 4 is a selective modulator of IL-17, functioning as a proagent for IL-17 modulator 1, a potent and orally active IL-17 inhibitor. This compound exhibits significant biological activity in the modulation of IL-17A signaling pathways, making it valuable in the study of IL-17A mediated diseases. Research applications include investigating its role in inflammation, autoimmune disorders, infectious diseases, cancer, and precancerous syndromes.

IL-2-IN-1 is a potent inhibitor of interleukin-2 (IL-2), exhibiting an IC50 value of 1978 nM. It demonstrates significant antiproliferative activity, making it a valuable tool for research in immune modulation and cytokine signaling. This compound is ideal for studies focused on T cell regulation and potential therapeutic applications in autoimmune diseases and cancers linked to IL-2 signaling.

Abacavir hydroxyacetate is an orally active inhibitor of IL-20 and PRINS. This compound demonstrates significant immune modulation, effectively reducing the proliferation rate of skin cells in psoriasis. It serves as a valuable tool for investigating inflammatory skin disorders and potential therapeutic strategies in related research applications.

IL-1β-IN-2 is a potent inhibitor of interleukin-1 beta (IL-1β), a key mediator in inflammatory processes. This cannabigerol derivative exhibits significant anti-inflammatory and analgesic effects, making it a valuable tool for research into conditions driven by IL-1β signaling. IL-1β-IN-2 is suitable for studies focused on inflammatory diseases and pain management, aiding in the understanding and development of therapeutic strategies targeting IL-1β.

IL-17 Modulator 1 disodium is a potent inhibitor targeting the IL-17 signaling pathway. This compound demonstrates significant biological activity in mitigating inflammatory responses, making it valuable for research applications related to autoimmune conditions such as psoriasis, ankylosing spondylitis, and psoriatic arthritis. Its oral bioavailability further enhances its utility in preclinical studies aimed at understanding and developing therapies for IL-17 associated diseases.

IL-1β-IN-1 is a selective inhibitor of interleukin-1 beta (IL-1β), a key cytokine involved in inflammatory processes. This compound demonstrates significant anti-inflammatory and analgesic effects, making it a valuable tool in research focused on chronic inflammatory conditions and pain management. Its potency and specificity for IL-1β allow for detailed studies on its biological roles and therapeutic applications.

IL-17-IN-2 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.4 μM, as demonstrated in both HTRF and NHK assays. This compound effectively disrupts IL-17 signaling, making it valuable for research related to inflammatory diseases and immune response modulation. Its significant biological activity allows for exploration in therapeutic contexts targeting IL-17-mediated pathways.

MOR-106 is a humanized anti-IL-17C IgG1 monoclonal antibody that targets interleukin-17C, a cytokine involved in inflammatory responses. By binding specifically to IL-17C, MOR-106 inhibits the NF-κB signaling pathway, demonstrating an IC50 of 59 pM for human IL-17C and 55 pM for mouse IL-17C. This reagent effectively reduces skin inflammation and associated inflammatory factors in preclinical models of psoriasis and atopic dermatitis, making it a valuable tool for research into inflammatory skin disorders.

IL-17 Modulator 4 Sulfate targets the IL-17 signaling pathway, functioning as a proagent of IL-17 Modulator 1. This compound exhibits potent modulatory effects on IL-17A, making it a valuable tool for investigating IL-17A mediated diseases. Its applications extend across various fields, including inflammation, autoimmune disorders, infectious diseases, cancer, and precancerous syndromes, facilitating a deeper understanding of these conditions.

Larnefpendekin alfa is an anti-IL-15RA antibody designed to target and inhibit the interleukin-15 receptor alpha (IL-15RA). This fusion protein plays a pivotal role in modulating immune responses by interfering with IL-15 signaling pathways. Its primary applications include investigations into immune system regulation, potential therapeutic avenues in autoimmune diseases, and cancer immunotherapy. This reagent is valuable for research focused on cytokine interactions and immune cell activation.

Balekafusp alfa is an IgG1K human antibody specifically targeting interleukin-2 (IL-2). It exhibits anti-tumor activity, making it a valuable tool for cancer research and therapeutic studies. This reagent can aid in investigating the immunological mechanisms of IL-2 and its role in tumor progression. Additionally, researchers can utilize it to explore potential applications in immunotherapy and the modulation of immune responses.

IL-17-IN-5 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.1 μM. This compound is designed for research applications related to inflammatory diseases, facilitating the study of IL-17's role in various pathophysiological processes. IL-17-IN-5 can aid in the development of therapeutic strategies targeting IL-17 signaling pathways.

Triptoquinone B is a sesquiterpene alkaloid that functions as an interleukin-1 inhibitor. It exhibits significant inhibitory effects on the release of interleukin 1α and 1β from human peripheral mononuclear cells, making it a valuable reagent for studies focused on inflammatory processes and cytokine signaling. This compound is useful for research into immune responses and related therapeutic applications.

IRBP (651-670) human, mouse is an epitope derived from the conserved region of interphotoreceptor retinoid binding protein (IRBP), functioning primarily as a uveitis-inducing agent. This specific fragment has been shown to elevate levels of pro-inflammatory cytokines, including IL-1β, IL-6, TNFα, IL-17A, and IL-17F, within ocular tissues. Due to its conservation across human, mouse, and bovine species, IRBP (651-670) is valuable in the study of experimental autoimmune uveitis and related inflammatory processes in ocular research.

Xelafaslatide is a Fas receptor antagonist that effectively inhibits Fas receptor signaling, thereby blocking downstream apoptosis and inflammatory pathways. This compound demonstrates significant potential in suppressing neuroinflammation and microglial activation in glaucoma models, offering protection to retinal ganglion cells and preventing axonal degeneration. Xelafaslatide is relevant for research focused on glaucoma and related neurodegenerative conditions.

Dazupegleukin is an interleukin-2 derivative that functions primarily as an immunomodulator. It exhibits antineoplastic properties, making it a valuable candidate for research focused on cancer immunotherapy. The compound can enhance T-cell proliferation and activation, thus playing a significant role in studies aimed at understanding and manipulating immune responses against tumors. Its applications extend to exploring novel therapeutic strategies in oncology.